Literature summary for 3.4.21.109 extracted from

Paszti-Gere, E.; Barna, R.F.; Ujhelyi, G.; Steinmetzer, T.
Interaction exists between matriptase inhibitors and intestinal epithelial cells (2016), J. Enzyme Inhib. Med. Chem., 31, 736-741 .

Search for more literature for 3.4.21.109

Inhibitors

Inhibitors	Comment	Organism	Structure
3-[(2S)-2-[[(2',4'-dimethoxybiphenyl-3-yl)sulfonyl]amino]-3-(4-[2-(methylcarbamoyl)aminoethyl]piperidin-1-yl)-3-oxopropyl]benzenecarboximidamide	-	Sus scrofa
3-[(2S)-3-[4-(2-aminoethyl)piperidin-1-yl]-2-[[(2',4'-dichlorobiphenyl-3-yl)sulfonyl]amino]-3-oxopropyl]benzenecarboximidamide	-	Sus scrofa
4-(2-aminoethyl)-benzosulphonylfluoride	nonselective inhibitor	Sus scrofa

Organism

Organism	UniProt	Comment	Textmining
Sus scrofa	F1S6D6	-	-

Source Tissue

Source Tissue	Comment	Organism	Textmining
IPEC-J2 cell	intestinal IPEC-J2 cell monolayer	Sus scrofa	-

Substrates and Products (Substrate)

Substrates	Comment Substrates	Organism	Products	Comment (Products)	Rev.	Reac.
butyloxycarbonyl-Gln-Ala-Arg-7-amido-4-methylcoumarin + H2O	-	Sus scrofa	?	-	?

General Information

General Information	Comment	Organism
physiological function	suppression of matriptase activity by inhibitors 3-[(2S)-2-[[(2',4'-dimethoxybiphenyl-3-yl)sulfonyl]amino]-3-(4-[2-(methylcarbamoyl)aminoethyl]piperidin-1-yl)-3-oxopropyl]benzenecarboximidamide and 3-[(2S)-3-[4-(2-aminoethyl)piperidin-1-yl]-2-[[(2',4'-dichlorobiphenyl-3-yl)sulfonyl]amino]-3-oxopropyl]benzenecarboximidamide leads to decreased transepithelial electrical resistance of the cell monolayer and to an enhanced transport of fluorescently labelled dextran	Sus scrofa

Use of this online version of BRENDA is free under the CC BY 4.0 license. See terms of use for full details.

Release 2023.1 (January 2023)